Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. (NASDAQ: NTRA) is a diagnostic and research company in the medical laboratories industry, focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. The Natera news feed on Stock Titan highlights company announcements, clinical data readouts, collaborations, and financial updates that reflect how its testing platforms are used in practice and research.
Recent news has featured advances in molecular residual disease (MRD) testing with Signatera, including new multi-modal AI models that integrate longitudinal circulating tumor DNA, clinical data, digital pathology, and tumor sequencing to refine recurrence risk assessment and outcomes prediction. Natera also reports on large clinical studies and trial analyses in colorectal cancer and breast cancer, where Signatera is used to evaluate MRD, predict treatment response, and support risk stratification.
In women’s health, news items include the launch and validation of Fetal Focus, a single-gene non-invasive prenatal test that uses cell-free DNA from maternal blood to assess inherited conditions when partner testing is not available, as well as updates related to the broader prenatal and carrier screening portfolio. Organ health news may cover the use of Natera’s Prospera test in transplant rejection assessment and related research.
Investors and clinicians can also follow Natera’s announcements about AI collaborations, such as its work with NVIDIA to scale multimodal AI foundation models, and corporate updates including preliminary financial results and participation in healthcare conferences. For those tracking NTRA, this news page provides a centralized view of developments across oncology, women’s health, organ health, and AI-enabled diagnostics.
Natera, Inc. (NASDAQ: NTRA) announced a significant win as the U.S. Patent Office upheld the validity of its U.S. Patent No. 8,682,592, denying a challenge from a multi-national sequencing company. This patent covers innovative methods for generating genetic data from limited DNA quantities, crucial in non-invasive prenatal testing and oncology. The Patent Office's decision highlights Natera's pioneering role in cfDNA testing, with only 20% of similar challenges resulting in a favorable outcome. Natera's early priority date of 2005 further solidifies its leadership in the field.
Natera, Inc. (NASDAQ: NTRA) will present new data on its personalized tumor-informed molecular residual disease (MRD) test, Signatera, at the ESMO IO Virtual Congress on December 10, 2020. The study involves 581 muscle invasive urothelial carcinoma patients from the IMvigor010 trial, assessing adjuvant treatment with atezolizumab. Interim results indicate ctDNA-positive patients showed improved overall survival of 25.8 months with treatment versus 15.8 months with observation (HR=0.59). The findings underscore Signatera's potential for patient selection in personalized cancer therapy.
Natera (NASDAQ: NTRA) announced its participation in the 2020 virtual San Antonio Breast Cancer Symposium (SABCS) from December 8-11, 2020. The company will present new data on its Signatera tumor-informed circulating tumor DNA (ctDNA) assay. Highlights include two posters: one on Signatera as a predictive biomarker in the I-SPY2 Trial and the other on comprehensive plasma-based whole exome analysis in the Beyond BRCA study. These presentations emphasize Signatera's role in monitoring treatment response and addressing drug resistance in breast cancer.
Natera, Inc. (NASDAQ: NTRA) announced that the second-largest commercial health plan in the U.S. has expanded coverage for non-invasive prenatal testing (NIPT) to all singleton pregnancies. This follows recent coverage expansions by other major health plans, resulting in over 90% of commercially-covered lives now having average-risk NIPT coverage. Natera's unique SNP-based NIPT technology aims to enhance prenatal care and reduce false negatives and positives, significantly impacting health outcomes. The company's Panorama test is a leading NIPT, backed by extensive clinical evidence.
Natera, Inc. (NASDAQ: NTRA) announced that the largest health plan in the U.S. will now cover non-invasive prenatal testing (NIPT) for all pregnancies. This decision follows a recent guideline from the American College of Obstetricians and Gynecologists (ACOG), promoting aneuploidy screening for all patients. The expanded coverage addresses previous barriers to adoption, potentially increasing the average risk NIPT market, which remains underpenetrated. Natera aims for profitability in its Women's Health business by 2021, capitalizing on this expansion and the positive health outcomes associated with NIPT.
Natera (NASDAQ: NTRA) announced a study published in Annals of Oncology demonstrating its ctDNA assay, Signatera, can effectively monitor neoadjuvant chemotherapy (NAC) responses in breast cancer patients. The study involved 291 plasma samples from 84 patients, revealing that early ctDNA clearance is significantly associated with achieving pathologic complete response (pCR), which indicates better survival outcomes. The findings suggest Signatera could improve treatment decisions and outcomes for breast cancer patients, particularly in predicting metastatic recurrence.
Natera, Inc. (NASDAQ: NTRA) has appointed Dr. Monica Bertagnolli to its board of directors. Dr. Bertagnolli, a renowned oncology researcher and professor at Harvard Medical School, brings extensive clinical experience to the role. CEO Steve Chapman expressed confidence in her ability to drive the company’s vision of advancing MRD testing as a standard of care. Dr. Bertagnolli's involvement is expected to enhance Natera's innovation in ctDNA technology, particularly in the application of Signatera technology, which aims to improve patient outcomes in oncology.
Natera, Inc. (NASDAQ: NTRA) announced a live webcast presentation at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 1:30 p.m. PT (4:30 p.m. ET). Mike Brophy, Chief Financial Officer, will discuss the company's latest developments. The webcast will be accessible live and archived on investor.natera.com.
Natera, a leader in cell-free DNA testing, aims to transform disease management, focusing on women’s health, oncology, and organ health.
Natera, Inc. (NASDAQ: NTRA) announced new data for its personalized molecular residual disease assay, Signatera, at the SITC 35th Annual Meeting, held from November 9-14, 2020. The presentations highlighted Signatera's capability in monitoring immunotherapy responses in colorectal and breast cancer. Key findings included early detection of treatment response dynamics via circulating tumor DNA (ctDNA) analyses, demonstrating the assay's utility in clinical decision-making and the monitoring of treatment efficacy.
Natera (NASDAQ: NTRA) reported strong Q3 2020 results with total revenues of $98.1 million, a 26% increase from Q3 2019, driven by a 39.5% rise in product revenues. The company processed 262,000 tests, up 31% year-over-year. Gross profit reached $46.3 million with a 47% gross margin. However, operating expenses grew to $102.1 million, leading to a net loss of $58.3 million, or ($0.72) per share. Natera raised its 2020 revenue guidance, expecting $380 million to $390 million in total revenues.